Youngwoo Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Youngwoo Hwang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Hyeon-Ki Jang
Department of Biotechnology and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Chuncheon 24341, Korea
1 shared publication - Hyun-Ouk Kim
Kangwon National University
1 shared publication - Minse Kim
Division of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Chuncheon-si 24341, Gangwon-do, Republic of Korea
1 shared publication - Seongyu Lim
Division of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Chuncheon 24341, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 11 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1197
Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system is a gene-editing technology. Nanoparticle delivery systems have attracted attention because of the limitations of conventional viral vectors. In this review, we assess the efficiency of various nanoparticles, including lipid-based, polymer-based, inorganic, and extracellular vesicle-based systems, as non-viral vectors for CRISPR/Cas9 delivery. We discuss their advantages, limitations, and current challenges. By summarizing recent advancements and highlighting key strategies, this review aims to provide a comprehensive overview of the role of non-viral delivery systems in advancing CRISPR/Cas9 technology for clinical applications and gene therapy.
- 11 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1197
Open AccessAdvances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system is a gene-editing technology. Nanoparticle delivery systems have attracted attention because of the limitations of conventional viral vectors. In this review, we assess the efficiency of various nanoparticles, including lipid-based, polymer-based, inorganic, and extracellular vesicle-based systems, as non-viral vectors for CRISPR/Cas9 delivery. We discuss their advantages, limitations, and current challenges. By summarizing recent advancements and highlighting key strategies, this review aims to provide a comprehensive overview of the role of non-viral delivery systems in advancing CRISPR/Cas9 technology for clinical applications and gene therapy.